Exenatide was the first GLP-1 analog approved by the FDA in 2005. It is administered through subcutaneous injection twice daily, before major meals. Exenatide reduces
Founded year: | Not set |
Funding rounds: | Not set |
Total funding amount: | Not set |
Founded year: | Not set |
Funding rounds: | Not set |
Total funding amount: | Not set |